Aktis Oncology, Inc. · NASDAQ:AKTS
Aktis Oncology — Investor Presentation (May 2026)
16 slides from Aktis Oncology's investor presentation, May 5, 2026
Slide 1: AKY-2519 Clinical Development Strategy
AKY-2519 Clinical Development Strategy May 5, 2026 1
Slide 2: Disclaimer
Disclaimer Information in this presentation and the accompanying oral presentation contains forward-looking statements within the meaning of the Private Securities Litigation Act of 1995 that involve substantial risks and uncertainties about Aktis Oncology and the industry in which Aktis Oncology op
Slide 3: Agenda
Agenda • Aktis Corporate Overview • B7-H3 Overview & Broad, Differentiated Opportunity • AKY-2519 Clinical Development Strategy • Next Steps & Upcoming Milestones 3
Slide 4: Maximizing the impact of radiopharmaceuticals
Maximizing the impact of radiopharmaceuticals Novel and Differentiated Platform Two Clinical Programs Accomplished Addressing Large Market Leadership Team Tumor Types Strong Imaging Proof-of- Balance Sheet Concept in Patients Pillars of value Pipeline Isotope Supply of Potential First-in- from Multi
Slide 5: Aktis is advancing a novel pipeline for large patient populations
Aktis is advancing a novel pipeline for large patient populations PROGRAM TARGET/INDICATION DISCOVERY IND-ENABLING PHASE 1b PHASE 2/3 UPCOMING MILESTONES Nectin-4 expressing Ph1b ongoing AKY-1189 Fast Track Designation* solid tumors Prelim data in 1Q’27 B7-H3 expressing Imaging/ dosimetry data at AS
Slide 6: B7-H3 Overview and AKY-2519 Clinical Development Strategy
B7-H3 Overview and AKY-2519 Clinical Development Strategy 6
Slide 7: Broad clinical development strategy for AKY-2519
Broad clinical development strategy for AKY-2519 • Opportunity for broad clinical development of AKY-2519, a miniprotein radioconjugate targeting B7- H3 expressing solid tumors • Two-trial clinical development strategy enables evaluation of AKY-2519 in multiple patient subsets to efficiently generat
Slide 8: B7-H3 is a clinically validated high-potential multi-tumor target
B7-H3 is a clinically validated high-potential multi-tumor target Tum. cells Normal Tissue Normal Vessels & vessels Brain Breast Colon Tumor Kidney • B7-H3 highly expressed in various solid tumors, including mCRPC, lung cancer and Lung breast cancer, and minimal expression in normal organs1 • High e
Slide 9: Summarizing AKY-2519 (B7-H3) development to date
Summarizing AKY-2519 (B7-H3) development to date Generated from Aktis’ 48hr platform, AKY-2519 (B7-H3) has demonstrated promising in vivo results including survival benefit ST1273R (mCRPC PDX) Tumor uptake at 4h 1500 15 AKY-2519 tool compound, 1250 Vehicle Tumor volume (mm3) [225Ac]Ac-AKY-3212 (1.0
Slide 10: Clinical imaging and dosimetry data for AKY-2519 to be presented at the 2026 ASCO Annual Meeting
Clinical imaging and dosimetry data for AKY-2519 to be presented at the 2026 ASCO Annual Meeting AKY-2519, a novel B7-H3-targeted radioconjugate, and its biodistribution profile in patients with mCRPC* Data at ASCO will highlight Date and Time: May 30, 1:30 p.m. - 4:30 p.m. CDT biodistribution and u
Slide 11: Significant opportunity for B7-H3 as a differentiated radiopharmaceutical target in mCRPC and other indications
Significant opportunity for B7-H3 as a differentiated radiopharmaceutical target in mCRPC and other indications • PLUVICTO® estimated global peak sales ~$5.4 billion in B7-H3 is highly expressed in multiple solid tumors; Potential to unlock whitespace opportunities prostate cancer alone1 B7-H3 • Per
Slide 12: Anticipated advantages of a dedicated mCRPC clinical trial protocol
Anticipated advantages of a dedicated mCRPC clinical trial protocol Radiopharmaceuticals • Utilizes prostate cancer-specific RLT centers are a key treatment • Enables mCRPC-targeted dose finding and expansion modality for prostate as well as characterization of B7-H3 expression vs. cancer PSMA expre
Slide 13: mCRPC-dedicated Phase 1b trial designed to rapidly generate data in PLUVICTO-naïve and -experienced patients
mCRPC-dedicated Phase 1b trial designed to rapidly generate data in PLUVICTO-naïve and -experienced patients AKY-2519-01 Trial design Dose escalation: BOIN Backfill (n≈30/cohort; escalation pts included) THERAPY Backfill Dose 1 PLUVICTO-naïve THERAPY 12 MBq 225 [ Ac]Ac-AKY-2519 225 [ Ac]Ac-AKY-2519
Slide 14: Positioning AKY-2519 to demonstrate its broad potential to address unmet patient needs
Positioning AKY-2519 to demonstrate its broad potential to address unmet patient needs Multiple tumor types Two focused trials Rapid data generation • B7-H3 highly expressed in • Initiated mCRPC-dedicated • Preliminary data from Ph1b multiple solid tumors across Ph1b trial in PLUVICTO-naïve mCRPC tr
Slide 15: Multiple anticipated catalysts over the next 12 months
Multiple anticipated catalysts over the next 12 months 2026 2027 MAY’26 MAY'26 2H’26 2027 AKY-2519 (B7-H3) mCRPC Clinical imaging and Basket Ph1b trial start Prelim data from Ph1b Ph1b trial dosimetry data - ASCO mCRPC trial in 2027 1Q’27 Ph1b prelim data in AKY-1189 (Nectin-4) 1Q’27 2H’26 1Q’27 Cor
Slide 16: Thank You
Thank You — =